NKTX compared with RANI: revenue, margins and what each company keeps, and the suppliers and customers both name

NKTXNkarta, Inc.

Mkt capRevenueRevenue

RANIRani Therapeutics Holdings, Inc.

Mkt capRevenueRevenue

Compare

NKTXNkarta, Inc.

RANIRani Therapeutics Holdings, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

NKTX: latest quarter not drawable. RANI: latest quarter is a loss; flow not drawable.Method ›

Price

rebased to 0%

NKTX, solidRANI, dashed

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only NKTX 0

None

Shared 0

No disclosed counterparties: NKTX.

Only RANI 6

—Celltrionunlistedsupplier

—Chugai Pharmaceuticalunlistedsupplier

—ProGenunlistedsupplier

—ICLunlistedsupplier

2 more · RANI chain ›

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

NKTXNkarta, Inc.

1.54· pre 1.50· delayed

Mkt cap$109.6MRevenue—

RANIRani Therapeutics Holdings, Inc.

0.56· pre 0.54· delayed

Pre-marketNov 4 '26delayed

Mkt cap$77.5MRevenue$2MQ2 FY26

Compare

Pre-marketNov 4 '26delayed

NKTXNkarta, Inc.

RANIRani Therapeutics Holdings, Inc.

1.54pre 1.50delayed

Price

0.56pre 0.54delayed

$109.6M

Mkt cap

$77.5M

—

Revenue

$2MQ2 FY26

NKTX1.54vsRANI0.56Pre-marketNov 4 '26delayed